Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of PTC Therapeutics Inc (NASDAQ: PTCT) closed at $68.51 in the last session, up 3.66% from day before closing price of $66.09. In other words, the price has increased by $3.66 from its previous closing price. On the day, 1.41 million shares were traded. PTCT stock price reached its highest trading level at $69.26 during the session, while it also had its lowest trading level at $65.68.
Ratios:
We take a closer look at PTCT’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.74 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.80. For the most recent quarter (mrq), Quick Ratio is recorded 3.57 and its Current Ratio is at 3.62.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Truist on June 17, 2025, initiated with a Buy rating and assigned the stock a target price of $80.
On May 09, 2025, BofA Securities Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $68.
Citigroup Upgraded its Sell to Neutral on May 07, 2025, while the target price for the stock was maintained at $40.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 07 ’25 when Boulding Mark Elliott sold 3,375 shares for $63.43 per share. The transaction valued at 214,091 led to the insider holds 103,901 shares of the business.
Reeve Emma sold 25,562 shares of PTCT for $1,686,024 on Oct 03 ’25. The Director now owns 10,332 shares after completing the transaction at $65.96 per share. On Oct 03 ’25, another insider, Jacobson Allan Steven, who serves as the Director of the company, sold 12,000 shares for $65.00 each. As a result, the insider received 780,000 and left with 17,451 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTCT now has a Market Capitalization of 5442304000 and an Enterprise Value of 5926644736. As of this moment, PTC’s Price-to-Earnings (P/E) ratio for their current fiscal year is 9.82. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.23. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.08. Its current Enterprise Value per Revenue stands at 3.358 whereas that against EBITDA is 6.623.
Stock Price History:
The Beta on a monthly basis for PTCT is 0.58, which has changed by 0.7857336 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, PTCT has reached a high of $67.40, while it has fallen to a 52-week low of $35.51. The 50-Day Moving Average of the stock is 20.84%, while the 200-Day Moving Average is calculated to be 35.35%.
Shares Statistics:
According to the various share statistics, PTCT traded on average about 1.27M shares per day over the past 3-months and 1212490 shares per day over the past 10 days. A total of 79.38M shares are outstanding, with a floating share count of 76.03M. Insiders hold about 4.29% of the company’s shares, while institutions hold 99.42% stake in the company. Shares short for PTCT as of 1759190400 were 7136920 with a Short Ratio of 5.61, compared to 1756425600 on 6643065. Therefore, it implies a Short% of Shares Outstanding of 7136920 and a Short% of Float of 10.319999600000001.
Earnings Estimates
The market rating for PTC Therapeutics Inc (PTCT) is a result of the insights provided by 6.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.73, with high estimates of $0.59 and low estimates of -$1.38.
Analysts are recommending an EPS of between $8.75 and $7.53 for the fiscal current year, implying an average EPS of $8.1. EPS for the following year is -$2.11, with 6.0 analysts recommending between -$0.35 and -$3.26.
Revenue Estimates
According to 11 analysts,. The current quarter’s revenue is expected to be $178.18M. It ranges from a high estimate of $211.8M to a low estimate of $140.3M. As of. The current estimate, PTC Therapeutics Inc’s year-ago sales were $196.79MFor the next quarter, 11 analysts are estimating revenue of $214.37M. There is a high estimate of $330.82M for the next quarter, whereas the lowest estimate is $147.93M.
A total of 15 analysts have provided revenue estimates for PTCT’s current fiscal year. The highest revenue estimate was $1.86B, while the lowest revenue estimate was $1.66B, resulting in an average revenue estimate of $1.73B. In the same quarter a year ago, actual revenue was $806.78MBased on 15 analysts’ estimates, the company’s revenue will be $847.4M in the next fiscal year. The high estimate is $1.06B and the low estimate is $531.9M.
